**4. Conclusions**

TR is a common heart valve disease associated with high morbidity and mortality when conservatively managed. Surgery is currently the treatment of choice, though very few patients with isolated TR undergo TV surgery in the real-world setting due to high surgical risk. In recent years, different percutaneous treatment devices have been developed offering promising results with much lower procedural adverse outcomes. Further studies are needed to find which will benefit the most from these therapies.
